VIDEO: Bulevirtide improves quality of life in chronic HDV

Bulevirtide improved quality of life measures among patients treated for chronic hepatitis D virus, Maria Buti, MD, PhD, of the Hospital Universiario Valle Hebron, told Healio Gastroenterology.

In a multicenter, randomized, phase 3 study, researchers evaluated the health-related quality of life benefits as measured by the Hepatitis Quality of Life Questionnaire (HQLQ) following 24 weeks of either bulevirtide 2 mg (n = 49 patients with HDV) treatment or delayed treatment (n = 51 patients with HDV). From baseline to study conclusion, results yielded numeric improvements in all domains of the HQLQ among patients treated with bulevirtide. Measured outcomes included a greater than 5-point improvement in general health, bodily pain, vitality, mental health, hepatitis-specific limitations and hepatitis-specific health distress as well as a greater than 4-point improvement in social functioning and role-emotional domains. Among patients who underwent delayed treatment, Buti noted a greater than 5-point improvement in mental health and hepatitis-specific health distress as well as a greater than 4-point improvement in health-specific limitations.

Future research aims to investigate the burden of illness, course of disease and long-term effects of bulevirtide 2 mg treatment on patients with chronic HDV quality of life.